Empowering people, informing care decisions.
Managing squamous cell carcinoma is a significant clinical issue as deaths from SCC are now estimated to exceed those from melanoma. DecisionDx-SCC is a genomic test that was developed to predict metastatic risk for SCC patients with one or more risk factors. Providing higher positive predictive value than previously possible. The test classifies patients as low (Class 1), higher (Class 2A), or highest (Class 2B) biological risk of metastasis. This enables physicians to develop a more personalized and accurate treatment or management plan specifically for each patient’s individual tumor profile.
